Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis

Circulation: Cardiovascular Interventions

Volumn 8, Issue 10, 2015, Pages

  Cuculi, Florim ^a   Puricel, Serban ^b   Jamshidi, Peiman ^a   Valentin, Jeremy ^b   Kallinikou, Zacharenia ^b   Toggweiler, Stefan ^a   Weissner, Melissa ^c   Munzel, Thomas ^c   Cook, Stephane ^b   Gori, Tommaso ^c  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Bioresorbable vascular scaffold; optical coherence tomography; percutaneous coronary intervention; peristrut low intensity area; scaffold thrombosis; stent thrombosis

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; CELL COUNT; CLINICAL ARTICLE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMPLANTATION; INFLAMMATORY CELL; MALE; MIDDLE AGED; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSTHESIS FAILURE; SCAFFOLD THROMBOSIS; STENT COLLAPSE; STENT MALAPPOSITION; STENT THROMBOSIS; THROMBECTOMY; THROMBOCYTE AGGREGATION INHIBITION; ADVERSE EFFECTS; AGED; BLOOD VESSEL TRANSPLANTATION; DEVICE FAILURE ANALYSIS; DRUG ELUTING STENT; STATISTICS AND NUMERICAL DATA; THROMBOSIS; UTILIZATION;

BIOMATERIAL; EVEROLIMUS;

AGED; BIOCOMPATIBLE MATERIALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; DRUG-ELUTING STENTS; EQUIPMENT FAILURE ANALYSIS; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBOSIS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84945918792     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.002518     Document Type: Article

References (34)

1. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. doi: 10.1161/CIRCULATIONAHA.106.685313.
2. Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation. 2011;124:1283-1287. doi: 10.1161/CIRCULATIONAHA.110.976829.
3. Alfonso F, Suárez A, Pérez-Vizcayno MJ, Moreno R, Escaned J, Bañuelos C, Jiménez P, Bernardo E, Angiolillo DJ, Hernández R, Macaya C. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;50:2095-2097. doi: 10.1016/j. jacc.2007.08.015.
4. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-2434. doi: 10.1161/CIRCULATIONAHA.106.658237.
5. Lee CW, Kang SJ, Park DW, Lee SH, Kim YH, Kim JJ, Park SW, Mintz GS, Park SJ. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55:1936-1942. doi: 10.1016/j.jacc.2009.10.077.
6. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Jüni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-399. doi: 10.1161/CIRCULATIONAHA.109.854398.
7. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. doi: 10.1161/01. CIR.0000116202.41966.D4.
8. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012;7:1060-1061. doi: 10.4244/EIJV7I9A168.
9. Abizaid A, Ribamar Costa J Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong WF, Sudhir K, Serruys PW; ABSORB EXTEND investigators. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015;10:1396-1401. doi: 10.4244/EIJV10I12A243.
10. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9:1036-1041. doi: 10.4244/EIJV9I9A176.
11. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimuseluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43-54. doi: 10.1016/S0140-6736(14)61455-0.
12. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791-801. doi: 10.1016/j.jacc.2014.12.017.
13. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Munzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2014;10:1144-1153. doi: 10.4244/EIJY14M07-11.
14. Fernández-Rodríguez D, Brugaletta S, Otsuki S, Sabaté M. Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent? EuroIntervention. 2014;10:600, discussion 600. doi: 10.4244/EIJV10I5A103.
15. Miyazaki T, Panoulas VF, Sato K, Naganuma T, Latib A, Colombo A. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. Int J Cardiol. 2014;174:e72-e74. doi: 10.1016/j.ijcard.2014.04.108.
16. Ishibashi Y, Onuma Y, Muramatsu T, Nakatani S, Iqbal J, Garcia-Garcia HM, Bartorelli AL, Whitbourn R, Abizaid A, Serruys PW; ABSORB EXTEND Investigators. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention. 2014;10:449-457. doi: 10.4244/EIJV10I4A78.
17. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Dudeck D, Falk E, Falk E, Feldman MD, Fitzgerald P, Garcia-Garcia HM, Garcia H, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, Räber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Sonada S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T, Troels T, Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G; International Working Group for Intravascular Optical Coherence Tomography (IWGIVOCT). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59:1058-1072. doi: 10.1016/j.jacc.2011.09.079.
18. Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlendorf KH, Kauffman CR, Shishkov M, Kang DH, Halpern EF, Tearney GJ. Characterization of human atherosclerosis by optical coherence tomography. Circulation. 2002;106:1640-1645. doi: 10.1161/01. CIR.0000029927.92825.F6.
19. Otake H, Shite J, Ikeno F, Shinke T, Teramoto T, Miyoshi N, Ako J, Honda Y, Fitzgerald PJ, Hirata K. Evaluation of the peri-strut low intensity area following sirolimus-and paclitaxel-eluting stents implantation: insights from an optical coherence tomography study in humans. Int J Cardiol. 2012;157:38-42. doi: 10.1016/j.ijcard.2010.11.006.
20. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005;45:995-998. doi: 10.1016/j.jacc.2004.12.066.
21. Okabe T, Mintz GS, Buch AN, Roy P, Hong YJ, Smith KA, Torguson R, Gevorkian N, Xue Z, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol. 2007;100:615-620. doi: 10.1016/j.amjcard.2007.03.072.
22. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-1409. doi: 10.1016/j.jacc.2008.12.055.
23. Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation. 2009;119:657-659. doi: 10.1161/CIRCULATIONAHA. 108.842757.
24. Cuculi F, Dall'Armellina E, Manlhiot C, De Caterina AR, Colyer S, Ferreira V, Morovat A, Prendergast BD, Forfar JC, Alp NJ, Choudhury RP, Neubauer S, Channon KM, Banning AP, Kharbanda RK. Early change in invasive measures of microvascular function can predict myocardial recovery following PCI for ST-elevation myocardial infarction. Eur Heart J. 2014;35:1971-1980. doi: 10.1093/eurheartj/eht434.
25. Cuculi F, Herring N, De Caterina AR, Banning AP, Prendergast BD, Forfar JC, Choudhury RP, Channon KM, Kharbanda RK. Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction. Heart. 2013;99:1198-1203. doi: 10.1136/heartjnl-2012-303443.
26. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70:515-523. doi: 10.1002/ccd.21136.
27. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA; ABSORB Cohort A and B investigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv. 2011;78:3-12. doi: 10.1002/ccd.22864.
28. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-2441. doi: 10.1161/CIRCULATIONAHA.107.693739.
29. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910-916. doi: 10.1161/CIRCULATIONAHA.105.609057.
30. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. doi: 10.1016/j.jacc.2006.03.042.
31. Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330-342. doi: 10.1161/CIRCINTERVENTIONS.113.000990.
32. Tellez A, Afari ME, Buszman PP, Seifert P, Cheng Y, Milewski K, McGregor JC, Garza JA, Roberts MB, Yi GH, Kaluza GL, Granada JF. Peri-strut low-intensity areas in optical coherence tomography correlate with peri-strut inflammation and neointimal proliferation: an in-vivo correlation study in the familial hypercholesterolemic coronary swine model of in-stent restenosis. Coron Artery Dis. 2014;25:595-601. doi: 10.1097/MCA.0000000000000134.
33. Otsuka F, Nakano M, Ladich E, Kolodgie FD, Virmani R. Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement. Thrombosis. 2012;2012:608593. doi: 10.1155/2012/608593.
34. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138-1145. doi: 10.1161/CIRCULATIONAHA.107.762047.